HC Wainwright Reiterates Buy Rating on Silence Therapeutics
HC Wainwright maintains a buy rating on Silence Therapeutics, setting a $75 price target, a 896.02% upside from the current price.
Key Points
- On June 17, 2026, HC Wainwright reiterated its buy rating on Silence Therapeutics (NasdaqGM:SLN) with a $75 price target.
- HC Wainwright's $75 price target implies 896.02% upside from Silence Therapeutics plc's ($SLN) current $7.53 share price.
- Silence Therapeutics, trading at $6.71, has a market cap of $319.3 million and a forward P/E of -17.33.
- Richard Ian Griffiths recently purchased shares, and peers like Citadel Advisors increased holdings significantly.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, HC Wainwright reiterated its buy rating on Silence Therapeutics plc (NasdaqGM:SLN), maintaining a price target of $75. Analyst Patrick R. Trucchio continues to see strong potential for the biotechnology company, which specializes in gene-silencing therapies.
Other Institutional Activity in Silence Therapeutics
Several institutional investors have been active in Silence Therapeutics. Nantahala Capital Management increased its holdings by 604,304 shares, bringing its total to 2,146,731 shares valued at approximately $11.3 million. Citadel Advisors made a significant move, adding 990,746 shares to hold a total of 1,234,807 shares worth about $6.5 million. Meanwhile, TCG Crossover Management, Siren, and Redmile Group maintained their positions without change.
Silence Therapeutics plc Stock Down 43.9%
Shares of NasdaqGM:SLN are trading at $6.71. The company has a market cap of approximately $319.3 million and a forward P/E ratio of -17.33, indicating it is not currently profitable. With a beta of 1.484, the stock shows some volatility. Over the past 52 weeks, the stock has ranged from $4.19 to $8.40, with a 50-day moving average of $6.81 and a 200-day moving average of $6.08. The company maintains a strong liquidity position with a current ratio of 9.83 and a quick ratio of 8.82, alongside a low debt-to-equity ratio of 0.275.
Recent Earnings
Silence Therapeutics reported revenue of $839,000, with a modest growth rate of 1.97%. The company is not yet profitable, reflected in its negative net margin and return on equity of -92.56%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Silence Therapeutics plc
Insider Richard Ian Griffiths has been actively buying shares of Silence Therapeutics. On October 27, 2025, he purchased 8,000 shares, and earlier on August 3, 2025, he bought 20,000 shares. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 17, 2026, HC Wainwright & Co. reiterated its buy rating for Silence Therapeutics, setting a price target of $75. The consensus among analysts is a buy, with an average target price of $31.20 based on five opinions. Other firms like Chardan Capital and Morgan Stanley also maintain buy ratings, with targets of $35 and $25 respectively, while Goldman Sachs has a sell rating with a $3 target.
About Silence Therapeutics
Silence Therapeutics plc is a biotechnology company based in London, UK. It focuses on developing therapies that use short interfering ribonucleic acid (siRNA) to silence specific genes. The company is advancing several candidates, including Divesiran for polycythemia vera and Zerlasiran for cardiovascular disease. Led by CEO Iain Gladstone Ross, the company employs about 88 people.
Bottom Line
HC Wainwright's reiterated buy rating and $75 price target underscore the potential seen in Silence Therapeutics' innovative gene-silencing approach. While the company is not yet profitable, its strong liquidity and ongoing developments in the biotechnology sector make it one to watch. Keep in mind that analyst ratings are based on past filings and may not reflect current conditions.
Get Silence Therapeutics plc alerts
New 13F filings, insider trades, and analyst moves on $SLN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.